A multisite phase II clinical trial to evaluate the immunogenicity and safety of ALVAC-HIV vCP1452 alone and combined with MN rgp120

Trial Profile

A multisite phase II clinical trial to evaluate the immunogenicity and safety of ALVAC-HIV vCP1452 alone and combined with MN rgp120

Completed
Phase of Trial: Phase II

Latest Information Update: 21 Aug 2009

At a glance

  • Drugs HIV vaccine vCP1452 (Primary) ; MN-rgp120 HIV-1 vaccine
  • Indications HIV infections
  • Focus Adverse reactions; Pharmacodynamics
  • Most Recent Events

    • 11 Aug 2009 Actual end date (1 Jul 2004) added as reported by ClinicalTrials.gov.
    • 11 Aug 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 28 Sep 2008 Actual patient number (160) added as reported by CT.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top